scispace - formally typeset
R

Ravi Kant Rajpoot

Researcher at International Centre for Genetic Engineering and Biotechnology

Publications -  15
Citations -  593

Ravi Kant Rajpoot is an academic researcher from International Centre for Genetic Engineering and Biotechnology. The author has contributed to research in topics: Dengue virus & Dengue vaccine. The author has an hindex of 9, co-authored 15 publications receiving 466 citations. Previous affiliations of Ravi Kant Rajpoot include University of California, Irvine.

Papers
More filters
Journal ArticleDOI

Vitamin k3 inhibits protein aggregation: Implication in the treatment of amyloid diseases

TL;DR: It is demonstrated that vitamin k3 significantly inhibits fibril formation as well as the inhibitory effect is dose dependent manner, paving the way for discovery of other small molecules that may exert similar effect against amyloid formation and its associated neurodegenerative diseases.
Journal ArticleDOI

Ascorbic acid inhibits human insulin aggregation and protects against amyloid induced cytotoxicity.

TL;DR: It is demonstrated that ascorbic acid significantly inhibits the fibrillation of HI in a dose-dependent manner and Interestingly ascorBic acid destabilise the preformed amyloid fibrils and protects human neuroblastoma cell line (SH- SY5Y) against amyloids induced cytotoxicity.
Journal ArticleDOI

Interplay of multiple interaction forces: Binding of tyrosine kinase inhibitor nintedanib with human serum albumin

TL;DR: Results demonstrate that fluorescence intensity of human serum albumin (HSA) gets quenched by NIB and quenching occurs in static manner and nintedanib increase the thermostability of HSA.
Journal ArticleDOI

Biomimetically synthesized ZnO nanoparticles attain potent antibacterial activity against less susceptible S. aureus skin infection in experimental animals

TL;DR: The biomimetically synthesized ZnO–NPs successfully treated the S. aureus mediated experimental skin infection in BALB/c mice as well as inhibited less susceptible Gram-positive and Gram-negative bacterial isolates.
Journal ArticleDOI

Pichia pastoris-Expressed Bivalent Virus-Like Particulate Vaccine Induces Domain III-Focused Bivalent Neutralizing Antibodies without Antibody-Dependent Enhancement in Vivo.

TL;DR: The creation and characterization of a novel non-replicating recombinant particulate vaccine candidate, produced by co-expressing the E proteins ofDENV-1 and DENV-2 in P. pastoris, and the results obtained with these bivalent mVLPs suggest the feasibility of incorporating the E protein of DENv-3 and DENVs-4 to create a tetravalent mVLP vaccine.